FDA approved Ingrezza (valbenazine) for tardive dyskinesia

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

FDA approved Ingrezza (valbenazine) for the treatment of adults with tardive dyskinesia

Tardive dyskinesia is a neurological disorder associated with repetitive involuntary movements of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips. Some people may experience involuntary movement of the extremities or difficulty in breathing.

Tardive dyskinesia is a serious side effect sometimes observed in patients receiving long-term treatment with older antipsychotic medications for chronic condition such as schizophrenia and bipolar disorder and for depression and certain medications for gastrointestinal disorders and other conditions. Why some people taking these medications develop tardive dyskinesia is still unclear.

The efficacy of Ingrezza was established in a cl...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I recall of Zenith Alpha Thoracic Endovascular Graft by Cook Medical – thrombus may form inside the device

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of lorazepam oral concentrate, USP 2mg/mL - defect in the dropper markings

Read more
  • FDA Drug Updates
  • 1 comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Potential complication associated with liquid-filled intragastric balloon systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of pravastatin sodium tablets by International Laboratories: Mislabeled and contained different drug

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of all liquid products manufactured by PharmaTech: Risk of product contamination

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Alert: Lack of sterility assurance for sterile drug products from Vital Rx, dba Atlantic Pharmacy and Compounding

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Hepatitis C

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Nerlynx (neratinib) for breast cancer

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA advise not to use any liquid product manufactured by PharmaTech due to possible contamination

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA warning against the use of Balguti Kesaria Ayurvedic Medicine due to risk of lead poisoning

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Investigation: Hypersensitivity reaction due to ungraded ingredient in curcumin emulsion for Injection by ImprimisRx

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Endari (L-glutamine) for sickle cell disease

Read more
  • MedWatch Drug Updates
  • no comment

Recall of Novopen Echo Insulin Delivery Device by Novo Nordisk: Chemical exposure may damage cartridge holder

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Atar Extension Cables by Oscor- cable malfunction interrupting the pacing system

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Diocto Liquid and Diocto Syrup by Rugby Laboratories: Risk of product contamination

Read more
  • FDA Drug Updates
  • 1 comment

FDA expands approved use of Imbruvica (ibrutinib) for chronic graft versus host disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of cyclobenzaprine and amantadine by Apace Packaging due to a potential mislabeling

Read more
  • MedWatch Drug Updates
  • 1 comment

Safety alert against compounded triamicinolone and moxifloxacin intravitreal Inj by Guardian Pharmacy Services

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Haegarda (C1 esterase inhibitor) for Hereditary Angioedema

Read more
  • MedWatch Drug Updates
  • 1 comment

Field Correction of system CS100, CS100i and CS300 Intra-Aortic Balloon Pumps by Datascope

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Navigational accuracy errors associated with frameless stereotaxic navigation systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Read more
  • MedWatch Drug Updates
  • no comment

Recall of one lot Eliquis 5 mg tablets by Bristol-Myers Squibb- Contain product of incorrect strength

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of topical products by Phillips Company- Improper manufacturing practices affecting product's quality

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of all unexpired sterile drug products by Cantrell Drug Company- Lack of sterility assurance

Read more